Heterodimeric Antibody Production via Asymmetric CH3 Interface Engineering
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing bispecific antibodies and multivalent multimers face challenges such as heavy and light chain miss-pairings, leading to impurities like halfbodies and homodimers, which complicate purification and reduce efficiency, necessitating improved technologies for producing and purifying these biological therapeutics.
Innovation Solution
The development of heterodimeric proteins with specific amino acid variants, such as L351D and T366K in one CH3 domain and L351K in another, along with variants at positions S364, K409, and K360, to enhance heterodimer formation and stability, and destabilize homodimers, facilitating purification through ion exchange chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If two antibodies are expressed in a single cell using recombinant DNA technology, then bispecific antibodies can be produced, but heavy and light chain miss-pairings occur leading to impurities like homodimers and halfbodies
Solution Approach 1:
The patent introduces asymmetric amino acid substitutions at the CH3-CH3 interface (L351D in one heavy chain and T366K in the other heavy chain). These asymmetric charge modifications create complementary electrostatic interactions that specifically promote heterodimer formation while preventing homodimer formation, thereby resolving the chain miss-pairing problem
Solution Approach 2:
The patent modifies the electrostatic parameters at the CH3 domain interface by introducing charged amino acid substitutions (L351D, T366K, L351K). These parameter changes alter the interaction energies between heavy chains, creating favorable conditions for heterodimerization and unfavorable conditions for homodimerization
2Stability of the object's composition
If amino acid variants are introduced to promote heterodimer formation, then heterodimer stability increases, but homodimers may still form as impurities
Solution Approach 1:
By introducing asymmetric charge substitutions (L351D in one chain, T366K and L351K in the other), the patent creates an interface where heterodimers benefit from complementary charge interactions while homodimers experience electrostatic repulsion or lack of favorable interactions, thereby stabilizing heterodimers and preventing homodimer formation
Solution Approach 2:
The patent converts the potential harm of charge modifications (which could destabilize the complex) into a benefit by strategically placing opposite charges at the interface. The charge substitutions that might seem disruptive actually promote specific heterodimer formation through complementary electrostatic attraction
3Productivity
If multiple heavy chains with variations are expressed to drive heterodimer formation, then bisspecific antibody production increases, but three different antibody species and halfbody impurities are generated
Solution Approach 1:
The asymmetric charge substitutions create a system where only specific heavy chain pairings (heterodimers) are stabilized. This asymmetry ensures that even when multiple heavy chains are expressed, only the intended bisspecific heterodimers form efficiently, while other combinations (homodimers, mismatched pairs) are thermodynamically disfavored
Solution Approach 2:
By modifying the electrostatic parameters at the CH3 interface, the patent changes the binding affinity landscape to favor heterodimer formation. This parameter change increases productivity by directing the expression system toward the desired product while minimizing impurity generation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in high-yield, predominantly heterodimeric proteins with improved stability and purity, simplifying the purification process and increasing the efficiency of the expression system by reducing unwanted species like halfbodies and homodimers.
Implementation Method 1
facilitating purification through ion exchange chromatography
Data Source
AI summary
The invention relates to heterodimeric proteins, and their methods of production and collection, that are useful to treat human disease.